No, cannabis has not been shown to treat Huntington’s disease or slow its progression. Three small controlled trials of CBD, nabilone and nabiximols (a THC and CBD spray) found the drugs were reasonably safe but produced little or no consistent improvement in movement, thinking or behavior. The National Academies rates the evidence as insufficient to support or refute benefit.
Huntington’s disease is an inherited brain disorder that causes involuntary movements called chorea, along with changes in mood, behavior and thinking. Because cannabinoid receptors are concentrated in the parts of the brain Huntington’s damages first, researchers have long wondered whether cannabis compounds could help. This guide reviews the human trials, the lab research behind the theory, and what patients and families should weigh, as of October 2026.
Cannabis and Huntington’s Disease: Evidence at a Glance
| Claim | Evidence level | Source |
|---|---|---|
| Oral cannabinoids improve chorea or neuropsychiatric symptoms | Insufficient | National Academies 2017 |
| CBD improves Huntington’s symptoms | One small trial, no benefit over placebo | Consroe et al. 1991 |
| Nabilone improves chorea | Limited (one pilot crossover trial, small effect) | Curtis et al. 2009 |
| Nabiximols (Sativex) improves symptoms or slows disease | One pilot trial, no benefit detected | López-Sendón Moreno et al. 2016 |
| Cannabinoids protect brain cells in Huntington’s | Animal and lab studies only | Cited in the 2016 Sativex trial |
Why Researchers Looked at Cannabis
Huntington’s disease first damages the striatum, a deep brain region that helps control movement. The striatum is rich in CB1 cannabinoid receptors, and studies in mouse models found that these receptors are lost early in the disease. In some animal experiments, drugs that activate the cannabinoid system reduced damage to brain cells. The Spanish team that ran the 2016 Sativex trial cited this mouse work as their rationale.
That theory has not translated into clear benefit in people. Animal models of Huntington’s do not fully reproduce the human disease, and many drugs that protect neurons in mice fail in human trials.
The Human Trials
Early CBD case series, 1980s
A small open study in the 1980s gave CBD to a few people with Huntington’s and reported some improvement in chorea. Uncontrolled reports like this are easily swayed by expectations and by the natural ups and downs of symptoms, so the same group ran a proper trial.
CBD trial, 1991
In a controlled crossover study, 15 people with Huntington’s who were not taking antipsychotic drugs received CBD (about 10 mg per kilogram a day) or sesame oil placebo for six weeks each. There was no meaningful difference between CBD and placebo on chorea or other measures. The authors concluded CBD was neither helpful nor toxic at that dose (Consroe et al., Pharmacology Biochemistry and Behavior).
Nabilone pilot trial, 2009
A UK team randomized 44 patients to nabilone (1 or 2 mg) and placebo in a crossover design. Nabilone did not improve the main measure, total motor score. It did show a small improvement in chorea and in a neuropsychiatric inventory score, both secondary measures. No psychotic episodes occurred. The authors called for a larger trial, which has not been published (Curtis et al., Movement Disorders).
Sativex pilot trial, 2016
Researchers in Madrid gave 26 patients Sativex, a mouth spray with roughly equal THC and CBD, or placebo for 12 weeks each, up to 12 sprays a day. Sativex was safe and well tolerated, with no serious adverse events. But there were no differences in motor, cognitive, behavioral or functional scores, and no effect on blood markers of disease (López-Sendón Moreno et al., Journal of Neurology).
What This Adds Up To
In total, fewer than 100 people with Huntington’s have been studied in controlled cannabinoid trials, and none of the trials showed a clear benefit on its main outcome. The National Academies’ 2017 review concluded there was insufficient evidence to support or refute oral cannabinoids for chorea and related neuropsychiatric symptoms. Nothing published since then has changed that verdict.
That is not the same as proof that cannabis is useless. The trials were small and short, used modest doses, and some individual patients may respond. But there is no reliable evidence to recommend it, and no cannabis-based drug is approved for Huntington’s anywhere in the US.
Symptoms People Ask About
| Symptom | What the trials found |
|---|---|
| Chorea (involuntary movement) | No benefit with CBD or Sativex; small secondary improvement with nabilone |
| Irritability and behavior | Possible small benefit with nabilone on one scale; none with Sativex |
| Thinking and memory | No improvement in any trial |
| Disease progression | No evidence of slowing in humans |
Risks and Side Effects
- Psychiatric effects: Huntington’s often brings depression, anxiety, irritability and sometimes psychosis. THC can worsen anxiety and, in some people, trigger psychotic symptoms. The National Institute on Drug Abuse lists these mental health risks.
- Balance and falls: people with Huntington’s already have impaired balance, and THC adds dizziness and slower reaction time.
- Swallowing: smoking or vaping can irritate the airways, which matters for patients with swallowing problems and choking risk.
- Thinking: THC impairs attention and memory while active, on top of the disease’s cognitive effects.
- Drug interactions: CBD can change blood levels of other medicines, and cannabinoids add to sedatives.
- Cannabis use disorder: regular use can lead to dependence; see our article on marijuana addiction.
Talk to Your Doctor
Treatments with proven benefit for chorea and mood symptoms exist, and a Huntington’s specialist can adjust them. If you are considering cannabis, tell your neurologist which product and dose, and track symptoms before and after so effects can be judged. Ask about clinical trials; Huntington’s research is active, and a trial is the safest way to try an experimental approach. Family members should know that unregulated products can vary widely in strength.
Legal Status
Huntington’s disease is not a listed condition in every state medical cannabis program, and rules differ. Adults 21 and older can buy cannabis legally in adult-use states such as Washington and Oregon. Cannabis remains illegal under federal law; see our federal law guide.
Cannabis and Huntington’s Disease FAQ
Does CBD help Huntington’s disease?
The only controlled trial, published in 1991, found CBD worked no better than placebo for chorea or other symptoms. CBD was well tolerated at the dose tested.
Can cannabis slow Huntington’s disease?
There is no human evidence that it does. Protective effects have been seen only in animal models, and a 2016 trial of Sativex found no change in disease markers.
Does marijuana help chorea?
Results are mixed and weak. A small nabilone trial found a modest improvement in chorea, while CBD and Sativex trials did not.
Is Sativex approved for Huntington’s disease?
No. Sativex (nabiximols) is not FDA-approved for any use in the US, and the one trial in Huntington’s found no symptom benefit.
Is cannabis safe for someone with Huntington’s?
The trials found cannabinoids were generally tolerated, but THC can worsen anxiety, psychosis, balance and thinking, which are already affected by the disease. Discuss it with a specialist first.
Related reading: cannabis and Alzheimer’s disease, cannabis and multiple sclerosis, cannabis and Tourette syndrome, and our full cannabis research section.
For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.
